Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Nanda

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
ESMO Open|June 6, 2025
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United StatesR Nanda, C Yam, L Spring, et al.
Journal of Medical Virology|October 8, 2021
Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD<sup>TM</sup> ) recipients: Report from the eastern state of IndiaGirish C Dash, Subhra Subhadra, Jyotirmayee Turuk, et al.
Breast Cancer Research and Treatment|January 17, 2012
Phase II trial of temsirolimus in patients with metastatic breast cancerGini F Fleming, Cynthia X Ma, Dezheng Huo, et al.
Journal of Medical Virology|December 9, 2020
Saliva for diagnosis of SARS-CoV-2: First report from IndiaDebdutta Bhattacharya, Debaprasad Parai, Usha K Rout, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyS Adams, S Loi, D Toppmeyer, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation ProgramR P McKillip, B A Borden, P Galecki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
ESMO Open|June 6, 2025
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United StatesR Nanda, C Yam, L Spring, et al.
Journal of Medical Virology|October 8, 2021
Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD<sup>TM</sup> ) recipients: Report from the eastern state of IndiaGirish C Dash, Subhra Subhadra, Jyotirmayee Turuk, et al.
Breast Cancer Research and Treatment|January 17, 2012
Phase II trial of temsirolimus in patients with metastatic breast cancerGini F Fleming, Cynthia X Ma, Dezheng Huo, et al.
Journal of Medical Virology|December 9, 2020
Saliva for diagnosis of SARS-CoV-2: First report from IndiaDebdutta Bhattacharya, Debaprasad Parai, Usha K Rout, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trialL A Huppert, D Wolf, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyS Adams, S Loi, D Toppmeyer, et al.
ESMO Open|March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancerS Jacob, E L Mayer, N Kacik, et al.
Clinical Pharmacology and Therapeutics|December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation ProgramR P McKillip, B A Borden, P Galecki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Pageof 15